As a new enterprise Biosint group may encounter several environmental issues such as changes in the current legislation regarding the custom agencies, change in operation costs and in the conformation of the entrepreneurial group and the rising of new companies and the integration of transnational companies that compete in the same ground as Biosint in Mexico.

Within the gene synthesis, issues such as importation problems with custom agencies are present. At the same time suppliers may find some problems related to delayed, broken or missing deliveries of reagents. Also the equipment could present some technical or operational failures in the synthesizer or in the sequencer, hence with flawful operations one can find defective oligonucleotides and genes. In the supply chain the last operation or distribution of the product will find problems as well, basically the same problems that the suppliers may give, for instance the existence of broken or lost products.

Additionally there exist the potential risk that another biotechnology company sets a market goal on Mexico, specifically in the production and disponibility of genomic services and products. This scenario although its very unlikely in the near future, it is possible that in the long term big biotechnology companies will come and establish themselves in Mexico, due to the current economic stability that the country has, and its strategic position and leadership in latin-america. We plan to be well prepared and well established by the time these companies arrive to our initial market, by competing in quality and customer service terms; such as delivery time and specialized customer support.

Another risk we foresee, is our lack of experience in the mexican biotechnology industry. This may be an opportunity as it is a risk, since biotechnology is a very new and novel industry in Mexico and Latin America there is only a handful of experienced biotechnology companies in our region, and most of them are focused on pharmaceutical or food industry. Our modest experience in the molecular biology and synthetic biology can be exploited to feed their necessity for genomic services and supplies.

Finally there is the potential that our main customers, which are federally funded research institutes, will not require our services and/or products as often as we are predicting. This scenario may be possible if the new federal government does not invest in science and development of new technologies as it was promised during campaign. This would affect our selling capabilities due the high federal funding dependency of our scientific sector for financial subsistence, and the discrete growth of private biotechnology industry.